Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ECULIZUMAB Cause Multiple organ dysfunction syndrome? 208 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 208 reports of Multiple organ dysfunction syndrome have been filed in association with ECULIZUMAB (SOLIRIS). This represents 0.5% of all adverse event reports for ECULIZUMAB.

208
Reports of Multiple organ dysfunction syndrome with ECULIZUMAB
0.5%
of all ECULIZUMAB reports
187
Deaths
91
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From ECULIZUMAB?

Of the 208 reports, 187 (89.9%) resulted in death, 91 (43.8%) required hospitalization, and 30 (14.4%) were considered life-threatening.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ECULIZUMAB. However, 208 reports have been filed with the FAERS database.

What Other Side Effects Does ECULIZUMAB Cause?

Fatigue (4,858) Off label use (4,228) Haemoglobin decreased (3,028) Headache (2,699) Death (2,221) Pyrexia (1,948) Dyspnoea (1,819) Asthenia (1,732) Drug ineffective (1,644) Nausea (1,579)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which ECULIZUMAB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

ECULIZUMAB vs EDARAVONE ECULIZUMAB vs EDETATE ECULIZUMAB vs EDOXABAN ECULIZUMAB vs EDOXABAN TOSILATE ECULIZUMAB vs EFALIZUMAB

Related Pages

ECULIZUMAB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome ECULIZUMAB Demographics